Blog and news

Article | 12.10.2026

New Baveno VIII Guidelines Reinforce FibroScan^® and VCTE^® for Portal Hypertension Assessment

Webinar | 14.09.2026

Baveno VIII in Practice: How Non-Invasive Tests Are Reshaping Portal Hypertension Management

Article | 18.08.2026

How can liver fibrosis be assessed without a biopsy? The role of noninvasive tests and controlled-vibration pulse elastography

Article | 13.08.2026

CAP VS Abdominal Ultrasound

Article | 13.08.2026

MASLD vs MASH: what are the differences?

Press Release | 14.07.2026

Uniting the liver community: Introducing Liver UK

Webinar | 15.06.2026

FibroScan^® Guided VCTE^® : Best Practice Review and Clinical Insights

Webinar | 15.06.2026

Multidisciplinary management of MASLD–MASH: bridging diabetology and hepatology

Webinar | 15.06.2026

Connecting the Dots: From Metabolic Risk to Liver Disease — A Primary Care Approach

Other | 02.06.2026

Echosens Appoints Romain Baujard as Group Chief Executive Officer

White Paper | 17.04.2026

New White Paper – Vibration-Controlled Transient Elastography Explained

Webinar | 13.04.2026

Multidisciplinary management of MASLD–MASH: bridging diabetology and hepatology

Webinar | 07.04.2026

FibroScan^® Guided VCTE^®: Best Practice Review and Clinical Insights

Article | 06.11.2025

Statement on the acceptance by the FDA of Echosens’ Letter of Intent for Drug Development Tool (DDT)

Article | 16.09.2025

A New Era for Liver Care: Prof. Dr. Jörn Schattenberg on the EC Approval of Rezdiffra™ for MASH